尼达尼布和多西他赛在既往治疗过的肺非鳞状非小细胞肺癌患者中的疗效和安全性:一项多中心回顾性现实世界分析

IF 2.1 4区医学 Q3 ONCOLOGY Radiology and Oncology Pub Date : 2023-09-04 eCollection Date: 2023-09-01 DOI:10.2478/raon-2023-0040

Lidija Ljubicic, Urska Janzic, Mojca Unk, Ana Sophie Terglav, Katja Mohorcic, Fran Seiwerth, Lela Bitar, Sonja Badovinac, Sanja Plestina, Marta Korsic, Suzana Kukulj, Miroslav Samarzija, Marko Jakopovic

{"title":"尼达尼布和多西他赛在既往治疗过的肺非鳞状非小细胞肺癌患者中的疗效和安全性:一项多中心回顾性现实世界分析","authors":"Lidija Ljubicic, Urska Janzic, Mojca Unk, Ana Sophie Terglav, Katja Mohorcic, Fran Seiwerth, Lela Bitar, Sonja Badovinac, Sanja Plestina, Marta Korsic, Suzana Kukulj, Miroslav Samarzija, Marko Jakopovic","doi":"10.2478/raon-2023-0040","DOIUrl":null,"url":null,"abstract":"Background: The standard first-line systemic treatment for patients with non-oncogene addicted advanced nonsquamous non-small cell lung cancer (NSCLC) is immunotherapy with immune checkpoint inhibitors (ICI) and/or chemotherapy (ChT). Therapy after failing ICI +/- ChT remains an open question, and docetaxel plus nintedanib represent a valid second line option.Patients and methods: A multicenter retrospective trial of real-life treatment patterns and outcomes of patients with advanced lung adenocarcinoma treated with docetaxel plus nintedanib after the failure of ICI and/or ChT was performed. Patients from 2 Slovenian and 1 Croatian oncological center treated between June 2014 and August 2022 were enrolled. We assessed objective response (ORR), disease control rate (DCR), median progression free survival (PFS), median overall survival (OS), and safety profile of treatment.Results: There were 96 patients included in the analysis, with ORR of 18.8%, DCR of 57.3%, median PFS of 3.0 months (95% CI: 3.0-5.0 months), and a median OS of 8.0 months (95% CI: 7.0-10.0 months). The majority of patients (n = 47,49%) received docetaxel plus nintedanib as third-line therapy. The ORR for this subset of patients was 19.1%, with a DCR of 57.4%. The highest response rate was observed in patients who received second-line docetaxel plus nintedanib after first-line combination of ChT-ICI therapy (n = 24), with an ORR of 29.2% and DCR of 66.7% and median PFS of 4.0 months (95% CI: 3.0-8.0 months). Fifty-three patients (55.2%) experienced adverse events (AEs), most frequently gastrointestinal; diarrhea (n = 29, 30.2%), and increased liver enzyme levels (n = 17, 17.7%).Conclusions: The combination of docetaxel and nintedanib can be considered an effective therapy option with an acceptable toxicity profile for patients with advanced NSCLC after the failure of ICI +/- ChT.","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 3","pages":"397-404"},"PeriodicalIF":2.1000,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476899/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis.\",\"authors\":\"Lidija Ljubicic, Urska Janzic, Mojca Unk, Ana Sophie Terglav, Katja Mohorcic, Fran Seiwerth, Lela Bitar, Sonja Badovinac, Sanja Plestina, Marta Korsic, Suzana Kukulj, Miroslav Samarzija, Marko Jakopovic\",\"doi\":\"10.2478/raon-2023-0040\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The standard first-line systemic treatment for patients with non-oncogene addicted advanced nonsquamous non-small cell lung cancer (NSCLC) is immunotherapy with immune checkpoint inhibitors (ICI) and/or chemotherapy (ChT). Therapy after failing ICI +/- ChT remains an open question, and docetaxel plus nintedanib represent a valid second line option.Patients and methods: A multicenter retrospective trial of real-life treatment patterns and outcomes of patients with advanced lung adenocarcinoma treated with docetaxel plus nintedanib after the failure of ICI and/or ChT was performed. Patients from 2 Slovenian and 1 Croatian oncological center treated between June 2014 and August 2022 were enrolled. We assessed objective response (ORR), disease control rate (DCR), median progression free survival (PFS), median overall survival (OS), and safety profile of treatment.Results: There were 96 patients included in the analysis, with ORR of 18.8%, DCR of 57.3%, median PFS of 3.0 months (95% CI: 3.0-5.0 months), and a median OS of 8.0 months (95% CI: 7.0-10.0 months). The majority of patients (n = 47,49%) received docetaxel plus nintedanib as third-line therapy. The ORR for this subset of patients was 19.1%, with a DCR of 57.4%. The highest response rate was observed in patients who received second-line docetaxel plus nintedanib after first-line combination of ChT-ICI therapy (n = 24), with an ORR of 29.2% and DCR of 66.7% and median PFS of 4.0 months (95% CI: 3.0-8.0 months). Fifty-three patients (55.2%) experienced adverse events (AEs), most frequently gastrointestinal; diarrhea (n = 29, 30.2%), and increased liver enzyme levels (n = 17, 17.7%).Conclusions: The combination of docetaxel and nintedanib can be considered an effective therapy option with an acceptable toxicity profile for patients with advanced NSCLC after the failure of ICI +/- ChT.\",\"PeriodicalId\":21034,\"journal\":{\"name\":\"Radiology and Oncology\",\"volume\":\"57 3\",\"pages\":\"397-404\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476899/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiology and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2478/raon-2023-0040\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/raon-2023-0040","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景:非癌基因成瘾晚期非鳞状非小细胞肺癌(NSCLC)患者的标准一线全身治疗是免疫检查点抑制剂(ICI)和/或化疗(ChT)的免疫治疗。ICI +/- ChT失败后的治疗仍然是一个悬而未决的问题，多西他赛加尼达尼布是有效的二线选择。患者和方法:对晚期肺腺癌患者在ICI和/或ChT治疗失败后接受多西他赛加尼达尼布治疗的现实治疗模式和结果进行了一项多中心回顾性试验。2014年6月至2022年8月期间，来自2个斯洛文尼亚和1个克罗地亚肿瘤中心的患者接受了治疗。我们评估了客观缓解(ORR)、疾病控制率(DCR)、中位无进展生存期(PFS)、中位总生存期(OS)和治疗的安全性。结果:96例患者纳入分析，ORR为18.8%，DCR为57.3%，中位PFS为3.0个月(95% CI: 3.0-5.0个月)，中位OS为8.0个月(95% CI: 7.0-10.0个月)。大多数患者(n = 47,49%)接受多西他赛加尼达尼布作为三线治疗。该亚组患者的ORR为19.1%，DCR为57.4%。一线联合ChT-ICI治疗后，接受二线多西他赛+尼达尼布治疗的患者(n = 24)的缓解率最高，ORR为29.2%，DCR为66.7%，中位PFS为4.0个月(95% CI: 3.0-8.0个月)。53名患者(55.2%)出现不良事件(ae)，最常见的是胃肠道;腹泻(n = 29, 30.2%)和肝酶水平升高(n = 17, 17.7%)。结论:对于ICI +/- ChT治疗失败的晚期NSCLC患者，多西他赛联合尼达尼布可被认为是一种有效的治疗选择，且毒性可接受。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis.

Background: The standard first-line systemic treatment for patients with non-oncogene addicted advanced nonsquamous non-small cell lung cancer (NSCLC) is immunotherapy with immune checkpoint inhibitors (ICI) and/or chemotherapy (ChT). Therapy after failing ICI +/- ChT remains an open question, and docetaxel plus nintedanib represent a valid second line option.

Patients and methods: A multicenter retrospective trial of real-life treatment patterns and outcomes of patients with advanced lung adenocarcinoma treated with docetaxel plus nintedanib after the failure of ICI and/or ChT was performed. Patients from 2 Slovenian and 1 Croatian oncological center treated between June 2014 and August 2022 were enrolled. We assessed objective response (ORR), disease control rate (DCR), median progression free survival (PFS), median overall survival (OS), and safety profile of treatment.

Results: There were 96 patients included in the analysis, with ORR of 18.8%, DCR of 57.3%, median PFS of 3.0 months (95% CI: 3.0-5.0 months), and a median OS of 8.0 months (95% CI: 7.0-10.0 months). The majority of patients (n = 47,49%) received docetaxel plus nintedanib as third-line therapy. The ORR for this subset of patients was 19.1%, with a DCR of 57.4%. The highest response rate was observed in patients who received second-line docetaxel plus nintedanib after first-line combination of ChT-ICI therapy (n = 24), with an ORR of 29.2% and DCR of 66.7% and median PFS of 4.0 months (95% CI: 3.0-8.0 months). Fifty-three patients (55.2%) experienced adverse events (AEs), most frequently gastrointestinal; diarrhea (n = 29, 30.2%), and increased liver enzyme levels (n = 17, 17.7%).

Conclusions: The combination of docetaxel and nintedanib can be considered an effective therapy option with an acceptable toxicity profile for patients with advanced NSCLC after the failure of ICI +/- ChT.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Radiology and Oncology ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Radiology and Oncology is a multidisciplinary journal devoted to the publishing original and high quality scientific papers and review articles, pertinent to diagnostic and interventional radiology, computerized tomography, magnetic resonance, ultrasound, nuclear medicine, radiotherapy, clinical and experimental oncology, radiobiology, medical physics and radiation protection. Therefore, the scope of the journal is to cover beside radiology the diagnostic and therapeutic aspects in oncology, which distinguishes it from other journals in the field.